5:41 PM
 | 
Oct 19, 2012
 |  BC Extra  |  Company News

CHMP backs Novo's insulin products

EMA's CHMP issued several positive opinions Friday, including recommending approval of two insulin products from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) to treat Type I and II diabetes: Tresiba insulin degludec and Ryzodeg insulin degludec/insulin aspart. The products are...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >